Valuation: PharmaEngine, Inc.

Market Cap 9.15B 286M 250M 230M 214M 407M 27.27B 413M 2.76B 1.07B 13.4B 1.07B 1.05B 46.19B P/E 2024
7.42x
P/E 2025 26.2x
Enterprise Value 4.48B 140M 122M 113M 105M 199M 13.34B 202M 1.35B 525M 6.56B 526M 515M 22.6B EV / Sales 2024
3.61x
EV / Sales 2025 5.97x
Free-Float
61.82%
Yield 2024
6.64%
Yield 2025 2.84%
1 day+4.43%
1 week+10.02%
Current month+4.43%
1 month+14.57%
3 months+7.97%
6 months-11.40%
Current year-9.52%
1 week 58.4
Extreme 58.4
65.6
1 month 53.4
Extreme 53.4
65.6
Current year 53
Extreme 53
74
1 year 53
Extreme 53
81.5
3 years 53
Extreme 53
123
5 years 53
Extreme 53
150.5
10 years 33.1
Extreme 33.1
212.51
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 17/05/2021
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member - 19/01/2018
Director/Board Member - 15/05/2018
Director/Board Member - 13/06/2019
Change 5-day change 1-year change 3-year change Capi.($)
+4.43%+10.02%-18.96%-33.16% 275M
+1.70%+7.41%+3.12%+8.46% 49.15B
+0.92%+3.93%+399.71%+605.33% 40.23B
+1.89%+8.32%+26.06%-6.35% 34.55B
+2.38%+6.35%+21.25%+64.58% 33.09B
+3.96%+10.67%+11.89%+38.86% 25.19B
+2.51%+5.27% - - 17.05B
+2.58%+5.79%+73.44%+133.27% 15.92B
+0.32%+0.58%+13.67%+19.09% 13.83B
+3.30%+0.76%+90.23%+99.12% 13.52B
Average +2.40%+5.72%+68.93%+103.25% 24.28B
Weighted average by Cap. +2.05%+6.10%+91.74%+139.01%

Financials

2024 2025
Net sales 2.52B 78.95M 69.02M 63.43M 59.13M 112M 7.52B 114M 762M 296M 3.7B 296M 290M 12.73B 911M 28.52M 24.93M 22.91M 21.36M 40.51M 2.72B 41.12M 275M 107M 1.33B 107M 105M 4.6B
Net income 1.75B 54.79M 47.9M 44.02M 41.03M 77.82M 5.22B 79M 528M 205M 2.56B 206M 201M 8.84B 388M 12.13M 10.6M 9.74M 9.08M 17.23M 1.15B 17.49M 117M 45.48M 568M 45.53M 44.55M 1.96B
Net Debt -3.85B -121M -105M -96.87M -90.3M -171M -11.48B -174M -1.16B -452M -5.64B -453M -443M -19.45B -4.67B -146M -128M -118M -110M -208M -13.93B -211M -1.41B -548M -6.85B -549M -537M -23.59B
Logo PharmaEngine, Inc.
PharmaEngine Inc is a Taiwan-based company primarily engaged in new drug development. The main business is the research and development of various cancer drugs. ONIVYDE is a novel and stable encapsulated form of the marketed chemotherapy drug irinotecan in a long-circulating nanoliposome for the treatment of patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy. It has received marketing approvals in Taiwan, the United States, the European Union, Singapore, South Korea, Japan, China and other regions. PEP07, a checkpoint kinase 1 (CHK1) inhibitor, which targets the deoxyribonucleic acid damage response (DDR) network, is in Phase 1 clinical trial stage and its target is to treat hematologic cancers such as acute myeloid leukemia (AML) and mantle cell lymphoma (MCL), and solid tumors.
Employees
45
Date Price Change Volume
03/07/26 NT$63.70 +4.43% 2,247,085
02/07/26 NT$61.00 -2.71% 785,072
01/07/26 NT$62.70 +2.79% 1,911,016
30/06/26 NT$61.00 +2.52% 2,624,725
29/06/26 NT$59.50 +2.76% 1,066,021
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4162 Stock